Cargando…
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
The sustainability of coronavirus 19 (COVID-19) vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to be determined to inform public health decisions on vaccination programs and prevention measures against COVID-19. The aim of the present study...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687721/ https://www.ncbi.nlm.nih.gov/pubmed/34938959 http://dx.doi.org/10.1097/HS9.0000000000000677 |
_version_ | 1784618231038738432 |
---|---|
author | Terpos, Evangelos Karalis, Vangelis Ntanasis-Stathopoulos, Ioannis Apostolakou, Filia Gumeni, Sentiljana Gavriatopoulou, Maria Papadopoulos, Dimitris Malandrakis, Panagiotis Papanagnou, Eleni-Dimitra Korompoki, Eleni Kastritis, Efstathios Papassotiriou, Ioannis Trougakos, Ioannis P. Dimopoulos, Meletios A. |
author_facet | Terpos, Evangelos Karalis, Vangelis Ntanasis-Stathopoulos, Ioannis Apostolakou, Filia Gumeni, Sentiljana Gavriatopoulou, Maria Papadopoulos, Dimitris Malandrakis, Panagiotis Papanagnou, Eleni-Dimitra Korompoki, Eleni Kastritis, Efstathios Papassotiriou, Ioannis Trougakos, Ioannis P. Dimopoulos, Meletios A. |
author_sort | Terpos, Evangelos |
collection | PubMed |
description | The sustainability of coronavirus 19 (COVID-19) vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to be determined to inform public health decisions on vaccination programs and prevention measures against COVID-19. The aim of the present study was to prospectively evaluate the kinetics of neutralizing antibodies (NAbs) and anti-S-receptor binding domain (RBD IgGs) against SARS-CoV-2 after full vaccination with the BNT162b2 mRNA vaccine for up to 9 months in healthy individuals (NCT04743388). The assessments were performed at the following time points after the second vaccination: 2 weeks, 1 month, 3 months, 6 months, and 9 months. The measurements were performed with the GenScript’s cPassTM SARS-CoV-2 NAbs Detection Kit (GenScript, Inc.; Piscataway, NJ) and the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics GmbH; Mannheim, Germany). Three hundred nine participants with a median age of 48 years were included. A gradual decline in both NAbs and anti-S-RBD IgGs became evident from 2 weeks to 9 months postvaccination. Both NAbs and anti-S-RBD IgGs levels were significantly lower at 9 months compared with the previous timepoints. Interestingly, age was found to exert a statistically significant effect on NAbs elimination only during the first-trimester postvaccination, as older age was associated with a more rapid clearance of NAbs. Furthermore, simulation studies predicted that the median NAb value would fall from 66% at 9 months to 59% and 45% at 12 and 18 months postvaccination, respectively. This finding may reflect a declining degree of immune protection against COVID-19 and advocates for the administration of booster vaccine shots especially in areas with emerging outbreaks. |
format | Online Article Text |
id | pubmed-8687721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-86877212021-12-21 Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals Terpos, Evangelos Karalis, Vangelis Ntanasis-Stathopoulos, Ioannis Apostolakou, Filia Gumeni, Sentiljana Gavriatopoulou, Maria Papadopoulos, Dimitris Malandrakis, Panagiotis Papanagnou, Eleni-Dimitra Korompoki, Eleni Kastritis, Efstathios Papassotiriou, Ioannis Trougakos, Ioannis P. Dimopoulos, Meletios A. Hemasphere Article The sustainability of coronavirus 19 (COVID-19) vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to be determined to inform public health decisions on vaccination programs and prevention measures against COVID-19. The aim of the present study was to prospectively evaluate the kinetics of neutralizing antibodies (NAbs) and anti-S-receptor binding domain (RBD IgGs) against SARS-CoV-2 after full vaccination with the BNT162b2 mRNA vaccine for up to 9 months in healthy individuals (NCT04743388). The assessments were performed at the following time points after the second vaccination: 2 weeks, 1 month, 3 months, 6 months, and 9 months. The measurements were performed with the GenScript’s cPassTM SARS-CoV-2 NAbs Detection Kit (GenScript, Inc.; Piscataway, NJ) and the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics GmbH; Mannheim, Germany). Three hundred nine participants with a median age of 48 years were included. A gradual decline in both NAbs and anti-S-RBD IgGs became evident from 2 weeks to 9 months postvaccination. Both NAbs and anti-S-RBD IgGs levels were significantly lower at 9 months compared with the previous timepoints. Interestingly, age was found to exert a statistically significant effect on NAbs elimination only during the first-trimester postvaccination, as older age was associated with a more rapid clearance of NAbs. Furthermore, simulation studies predicted that the median NAb value would fall from 66% at 9 months to 59% and 45% at 12 and 18 months postvaccination, respectively. This finding may reflect a declining degree of immune protection against COVID-19 and advocates for the administration of booster vaccine shots especially in areas with emerging outbreaks. Lippincott Williams & Wilkins 2021-12-17 /pmc/articles/PMC8687721/ /pubmed/34938959 http://dx.doi.org/10.1097/HS9.0000000000000677 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Terpos, Evangelos Karalis, Vangelis Ntanasis-Stathopoulos, Ioannis Apostolakou, Filia Gumeni, Sentiljana Gavriatopoulou, Maria Papadopoulos, Dimitris Malandrakis, Panagiotis Papanagnou, Eleni-Dimitra Korompoki, Eleni Kastritis, Efstathios Papassotiriou, Ioannis Trougakos, Ioannis P. Dimopoulos, Meletios A. Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals |
title | Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals |
title_full | Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals |
title_fullStr | Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals |
title_full_unstemmed | Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals |
title_short | Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals |
title_sort | sustained but declining humoral immunity against sars-cov-2 at 9 months postvaccination with bnt162b2: a prospective evaluation in 309 healthy individuals |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687721/ https://www.ncbi.nlm.nih.gov/pubmed/34938959 http://dx.doi.org/10.1097/HS9.0000000000000677 |
work_keys_str_mv | AT terposevangelos sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT karalisvangelis sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT ntanasisstathopoulosioannis sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT apostolakoufilia sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT gumenisentiljana sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT gavriatopouloumaria sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT papadopoulosdimitris sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT malandrakispanagiotis sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT papanagnouelenidimitra sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT korompokieleni sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT kastritisefstathios sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT papassotiriouioannis sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT trougakosioannisp sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals AT dimopoulosmeletiosa sustainedbutdeclininghumoralimmunityagainstsarscov2at9monthspostvaccinationwithbnt162b2aprospectiveevaluationin309healthyindividuals |